The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2014
At a glance
- Drugs JNJ 42165279 (Primary)
- Indications Anxiety disorders
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 14 Oct 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 25 Feb 2014 Planned End Date changed from 1 May 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 30 Sep 2013 Planned End Date changed from 1 Jan 2014 to 1 May 2014 as reported by ClinicalTrials.gov.